Trial Profile
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs WT1 peptide-loaded dendritic cell vaccine (Primary) ; Endotoxin; Interleukin-4; Keyhole limpet haemocyanin
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2015 as reported by ClinicalTrials.gov.